Centrally acting antihypertensive drugs: Re-emergence of sympathetic inhibition in the treatment of hypertension

Current Hypertension Reports

Volumn 1, Issue 4, 1999, Pages 305-312

  Benedict, Claude R ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; MOXONIDINE;

ADRENERGIC SYSTEM; ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 0033170535     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0038-1     Document Type: Article

References (52)

1. Sun MK: Central neural organization and control of sympathetic nervous system in mammals. Prog Neurobiol 1995, 47: 157-234.
2. Reis DJ: Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. J Cardiovasc Pharmacol 1996, 27(suppl 3):S11-S18. (Pubitemid 26282648)
3. Kjeldsen SE, Schork NJ, Leren P, Eide IK: Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989, 118: 775-781.
4. Qu L, Stuesse SL: Influence of substance P on carotid sinus nerve baro- and chemoreceptor activity in rabbits. Peptides 1990, 11: 955-961.
5. Long CS, Kariya K, Karns L, Simpson PC: Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol 1991, 17(suppl 2):S20-S24.
6. Rosen MR, Danilo P Jr, Robinson RB, et al.: Sympathetic neural and a-adrenergic modulation of arrhythmias. Ann N Y Acad Sci 1988, 533: 200-209.
7. Kaplan JR, Pettersson K, Manuck SB, Olsson G: Role of sympathoadrenal medullary activation in the initiation and progression of atherosclerosis. Circulation 1991, 84(suppl 6):VI23-VI32.
8. DiBona GF: Sympathetic neural control of the kidney in hypertension. Hypertension 1992, 19(suppl I):I28-I35.
9. DiBona GF, Jones SY, Sawin LL: Renal sympathetic neural mechanisms as intermediate phenotype in spontaneously hypertensive rats. Hypertension 1996, 27: 626-630.
10. Korner PI: Circulatory control and the supercontrollers. J Hypertens 1995, 13: 1508-1521.
11. Zimmerman RS, Frohlich ED: Stress and hypertension. J Hypertens 1990, 8:S103-S107. (Pubitemid 20338950)
12. Esler M, Ferrier C, Lamberg G, et al.: Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension 1991, 17(suppl III):III29-III35.
13. Ferrario CM, Averill DB: Do primary dysfunctions in neural control of arterial pressure contribute to hypertension? Hypertension 1991, 18(suppl I):I38-I51.
14. Julius S, Weder AB: Brain and the regulation of blood pressure: a hemodynamic perspective. Clin Exp Hypertens 1989; 11(suppl 1): 1-19.
15. Mark AL: Regulation of sympathetic nerve activity in mild human hypertension. J Hypertens Suppl 1990, 8:S67-S75.
16. Ward KD, Sparrow D, Landsberg L, et al.: Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the normative aging study. J Hypertens 1996, 14: 301-308.
17. DeQuattro V, Lee DD, Shkhvatasabaya IK, et al.: Primary hypertension, left ventricular mass and function, sympathetic nervous system activity, and therapy. Health Psychol 1988, 7(suppl): 165-173.
18. Frank C. Smith S: Stress and the heart: biobehavioral aspects of sudden cardiac death. Psychosomatics 1990, 31: 255-264.
19. Willich SN, Maclure M, Mittleman M, et al.: Sudden cardiac death. Support for a role of triggering in causation. Circulation 1993, 87: 1442-1450.
20. Fedida D, Bouchard RA: Mechanisms for the positive inotropic effect of a1 adrenoceptor stimulation in rat cardiac myocytes. Circ Res 1992, 71: 673-688.
21. Billman GE: Mechanisms responsible for the cardiotoxic effects of cocaine. FASEB J 1990, 4: 2469-2475.
22. Schomig A, Richardt G, Kurz T: Sympatho-adrenergic activation of the ischemic myocardium and its arrhythmogenic impact. Herz 1995, 20: 169-186.
23. Moratinos J, Reverte M: Effects of catecholamines on plasma potassium: the role of a- and b-adrenoceptors. Fundam Clin Pharmacol 1993, 7: 143-153.
24. Opie LH: Sympathetic stimulation of ischemic myocardium: role of plasma free fatty acids and potassium. J Cardiovasc Pharmacol 1988, 12(suppl 1):S31-S38.
25. Brown MJ, Brown DC, Murphy MB: Hypokalemia from b2-receptor stimulation by circulating epinephrine. N Engl J Med 1983, 309: 1414-1419.
26. Myers MG, Norris JW, Hachniski VC, Sole MJ: Plasma norepinephrine in stroke. Stroke 1981, 12: 200-204.
27. Anfossi G, Trovati M: Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996, 26: 353-370.
28. Pauletto P, Scannapieco G, Pessina AC: Sympathetic drive and vascular damage in hypertension and atherosclerosis Hypertension 1991, 17(suppl III):III75-III81.
29. Heusch G: a-Adrenergic mechanisms in myocardial ischemia. Circulation 1990, 81: 1-13.
30. Lee DD, Rigonan K, DeQuattro V: Increased blood pressure and neural tone in the silent ischemia of hypertension: disparate effects of immediate release nifedipine. J Am Coll Cardiol 1993, 22: 1438-1445.
31. Yurenev AP, DeQuattro V, Dubov PB, et al.: Silent myocardial ischemia in patients with essential hypertension. Am J Hypertens 1992, 5: 169-174.
32. Ernsberger P, Westbrooks KL, Christen MO, Schaefer SG: A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992, 20(suppl 4):S1-S10. (Pubitemid 23048800)
33. Ernsberger P, Collins LA, Graves ME, et al.: Imidazoline I1 receptors in the ventrolateral medulla and their role in cardiorespiratory control. In In Ventral Brainstem Mechanisms and Control Functions. Edited by Trouth O, Millis R, Kiwell- Schone H, Schlafke M. New York: Marcel Dekker; 1995:319-358.
34. Ernsberger P, Graves ME, Graff LM, et al.: I1-Imidazoline receptors: definition, characterization, distribution and transmembrane signaling. Ann N Y Acad Sci 1995, 763: 22-42.
35. Frei M, Kuster L, Gardosch-von Krosigk P-P, et al.: Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994, 24 (suppl 1):S25-S26.
36. Kuppers H, Jager B, Luszick J, et al.: Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997, 15: 93-97.
37. Lotti G, Gianrossi R: Moxonidin vs captopril bei leichter bis mittelschwerer hypertonie: doppelblindstudie zur wirksamkeit and vertraglichkeit. Fortschr Med 1993, 111: 429-432.
38. Kraft K, Vetter H: Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994, 24(suppl 1):S29-S35.
39. Prichard BNC: Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994, 8(suppl 1): 49-58.
40. Wolf R: The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992, 20(suppl 4):S42-S44. (Pubitemid 23048807)
41. Planitz V: Crossover comparison of moxonidine and clonidine in mild-to-moderate hypertension. Eur J Pharmacol 1984, 27: 147-152.
42. Planitz V, Hoffmann K, Stenzel W: A double-blind crossover trial of moxonidine hydrochloride monohydrate (BF5895) and clonidine hydrochloride in hypertensive patients. Naunyn Schmeidebergs Arch Pharmacol 1984, 325(suppl): 84-88.
43. Schwarz VW, Kandziora J: Langzeiterfahrungen mit moxonidin einem neuen antihypertensivum. Forschr Med 1990, 108: 64-70.
44. Trieb G, Jager B, Hughes PR, et al.: Long-term evaluation of the antihypertensive efficacy and tolerability of the orally-acting imidazoline I1 receptor agonist moxonidine in patients with mild to moderate essential hypertension. Eur J Clin Res 1995, 7: 227-240.
45. Schrader J, Schoel G, Gundlach K, et al.: Antihypertensive wirkdauer und morgendlicher blutdruckanstieg unter moxonidine in der ambulanten 24-stunden-blutdruckmessung. Nieren Hochdruckkrankh 1992, 21: 531-533.
46. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322: 1561-1566.
47. Pfeffer MA, Pfeffer JM: Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990, 322: 1388-1389.
48. Eichstadt H, Richter W, Bader M, et al.: Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989, 3(suppl 2): 583-587.
49. Motz W, Vogt M, Scheler S, Strauer BE: Hypertensive coronary microcirculation effects of the imidazoline-receptor-agonist moxonidine. Cardiovasc Risk Fact 1995, 5(suppl 1): 28-32.
50. Feuring M, Cassal D, Stewenov D, et al.: Safety of moxonidine in patients with mild-to-moderate hypertension and chronic pulmonary disease. Hospitalis 1996, 67:A553.
51. Kirch W, Planitz V: Klinische aspekte der therapie mit einem zentral wirksamen alpha2-adrenozeptor-agonisten bei patienten mit arterieller hypertonie. CorVas 1991, 5: 1-12.
52. Ongyert D, Dotzer F: Wirksamkeit und vergraglichkeit von moxonidin. Z Allg Med 1993, 69:S56-S60.